Navigation Links
BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Date:1/10/2008

pect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that DHHS and the FDA may not agree with our analysis, that DHHS may further condition, reduce or eliminate future funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient c
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. Medpace Strengthens Presence in Central Europe
5. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
6. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
7. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
8. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
9. Anavex strengthens Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... (Nasdaq: ANSV ) announced today that John P. ... Susquehanna Financial Group,SIGnificant Investment Options in Healthcare Conference in ... EDT., To access the live webcast or the ... to the Investors page, and click on Events.,Please connect ...
... An experimental, combination vaccine against Ebola and Marburg ... protection against infection in monkeys. Researchers from ... Diseases (USAMRIID) report their results today (Feb. 26) ... Research Meeting in Baltimore, MD. , VLPs are ...
... N.J., Feb. 26 SyntheMed, Inc. (OTC,Bulletin Board: ... commercialization of anti-adhesion products, drug delivery products and,other ... President,and CEO, will present at the Canaccord Adams, ... p.m. PST in San Francisco, CA. Mr.,Hickey will ...
Cached Biology Technology:Combination vaccine protects monkeys from ebola and Marburg viruses 2
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... of 10 new cancer drugs successfully clear preclinical ... clinical testing. A new partnership facilitated by SAIC-Frederick ... The partnership brings together The UC Davis Cancer ... Institute,s (NCI) Center for Advanced Preclinical Research (CAPR), ...
... from Germany, Malaysia, Vietnam, the Philippines, the UK, Bulgaria ... LEGATO, which will be launched on June 14, 2011, ... and Ecological Engineering Assessment Tools for risks and ... to advance long-term sustainable development of irrigated rice fields, ...
... huge plume of sulphur dioxide that spewed from Chile,s Puyehue-Cordn ... km south of Santiago. After lying dormant for more ... beginnings of this major volcanic eruption. On 4 June, a ... gas over 10 km high. ,Several thousand people were evacuated ...
Cached Biology News:NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 2NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 3LEGATO -- a major international project on sustainable development of rice ecosystems in Southeast Asia 2